Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: david james who wrote (677)	2/16/2000 5:01:00 PM
From: Tom Hua	of 1298

Wednesday February 16, 4:21 pm Eastern Time Company Press Release Robertson Stephens Reiterates Buy Rating on CEGE SAN FRANCISCO--(BUSINESS WIRE)--Feb. 16, 2000--Robertson Stephens Biopharmaceuticals Analyst Lesley Wright Marino today reiterated her Buy rating on Cell Genesys (NASDAQ:CEGE - news). ``We are reiterating our Buy rating on shares of Cell Genesys, as we believe the stock represents one of the best values in biotech today,' said Marino. ``We believe Cell Genesys has a promising cancer vaccine in Phase II studies, an intellectual property estate of more than 200 issued and allowed patents, a very strong financial position and a negative technology value.' Clients interested in receiving more information should contact their salesperson at (415) 781-9700.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next